IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Lorraine F. MEISNER

Group Art Unit: 1655

Serial Number: 10/614,768

Examiner: Michele C. Flood

Filing Date: 07/08/2003

CONFIRMATION NO: 8047

Title: TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND RELATED SKIN DISORDERS

FILED ELECTRONICALLY

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Sir:

An Information Disclosure Statement along with attached form PTO/SB/08 is hereby submitted. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

The listed information is respectfully requested to be considered by the Examiner and be made of record in the above-identified application. The Examiner is further requested to initial and return the attached form PTO/SB/08 in accordance with MPEP §609.

The right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered are reserved.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

A.	☐ 37 CF. because:	R §1.97	(b). This Information Disclosure Statement should be considered by the Office
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under §1.53(d);
			OR
		(2)	It is being filed within 3 months of entry of the national stage as set forth in §1.491 in an international application;
			OR
		(3)	It is being filed before the mailing of a first Office action on the merits;
			OR
		(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
В.	specified in	n <i>37 CF</i> on under ecution	(c). Although this Information Disclosure Statement is being filed after the period $R \ \S 1.97(b)$, above, it is filed before the mailing date of the earlier of (1) a final $\S 1.113$, (2) a notice of allowance under $\S 1.311$, or (3) an action that otherwise on the merits, this Information Disclosure Statement should be considered because y one of:
		a stater	ment as specified in §1.97(e) provided concurrently herewith;
			OR
	\boxtimes		f \$180.00 as set forth in \$1.17(p) authorized below, enclosed, or included with the nt of other papers filed together with this statement.
C.	date of the	earlier o	d). Although this Information Disclosure Statement is being filed after the mailing of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, fore payment of the issue fee and should be considered because it is accompanied
		i. a st	atement as specified in §1.97(e);
			AND
			ee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included he the payment of other papers filed together with this Statement.
D.	☐ 37 CFI	R §1.97(e). Statement.
		A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);
			AND/OR
		A state	ment is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);
			AND/OR
		informathe con	of a dated communication from a foreign patent office clearly showing that the ation disclosure statement is being submitted within 3 months of the filing date on mmunication is provided in lieu of a statement under 37 C.F.R. § 1.97(e)(1) as ed for under MPEP 609.04(b) V.
Е.	disclosure application	statemen that wa	der 37 C.F.R. §1.704(d). Each item of information contained in the information at was first cited in a communication from a foreign patent office in a counterpart is received by an individual designated in § 1.56(c) not more than thirty (30) days of this information disclosure statement. This statement is made pursuant to the

	for Applica	nt(s) delay.		
F.		$R \S 1.98(a)(2)$. The content of the Information Disclosure Statement is as follows:		
		Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.		
		OR		
		Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.		
		AND/OR		
	\boxtimes	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).		
		AND/OR		
	\boxtimes	Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).		
G.	37 CFI references.	R §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or		
		Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.		
		Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.		
		OR		
		A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:		
		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.		
Н.		R $\S1.98(d)$. Copies of patents, publications and pending U.S. patent applications, or other a specified in 37 C.F.R. \S 1.98(a) are not provided herewith because:		
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement, cited by examiner(s) for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.		
		Application in which the information was submitted:		
		Information Disclosure Statement(s) filed on:		
		AND		
		The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.		

requirements of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term

I. Fee Authorization. The Commissioner is hereby authorized to charge all fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 36091-702.301).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: March 3, 2008

Nicholas J. DiCeglie, Jr. Reg. No. 51,615

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971